Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination

British Journal of Cancer

Volumn 81, Issue 3, 1999, Pages 490-495

  Yu, H ^a   Levesque, M A ^b,c   Clark, G M ^d   Diamandis, E P ^b,c  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Breast neoplasms; ELISA; p53; Prostate specific antigen; Protein

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53;

ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; CELL CYCLE S PHASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PLOIDY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGRESSION ANALYSIS; TUMOR VOLUME;

AGE FACTORS; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DNA REPLICATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; LIFE TABLES; LYMPHATIC METASTASIS; MASTECTOMY; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; PLOIDIES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; RADIOTHERAPY, ADJUVANT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032882456     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690720     Document Type: Article

References (45)

1. Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osborne CK and McGuire WL (1993) Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200-206
2. Borg A, Lennerstrand J, Stenmark-Askmalm M, Ferno M, Brisfors A, Ohrvik A, Stal O, Killander D, Lane D and Brundell J (1995) Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols. Br J Cancer 71: 1013-1017
3. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR and Kley N (1995) Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377: 646-649
4. Chang F, Syrjnen, Tervabauta A and Syrjanen K (1993) Tumorigenesis associated with the p53 tumour suppressor gene. Br J Cancer 68: 653-661
5. Clark GM and McGuire WL (1983) Progesterone receptors and human breast cancer. Breast Cancer Res Treat 3: 157-163
6. Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T and McGuire WL (1989) Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320: 627-633
7. Clements J and Mukhtar A (1994) Glandular kallikreins and prostate specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab 78: 1536-1539
8. Cohen P, Graves HCB, Peehl DM, Kamarel M, Giudice LC and Rosenfeld RG (1992) Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein 3 protease found in seminal plasma. J Clin Endocrinol Metab 75: 1046-1053
9. Cohen P, Peehl DM, Graves HCB and Rosenfeld RG (1994) Biological effects of prostate specific antigen as an insulin-like growth factor-binding-3 protease. J Endocrinol 142: 407-415
10. Cox DR (1972) Regression models and life tables. J R Stat Soc B 34: 187-202
11. de Witte HH, Kockens JA, Lennerstrand J, Smid M, Look MP, Klijn JGM, Benraad TJ and Berns EMJJ (1996) Prognostic significance of TP53 accumulation in human primary breast cancer: comparison between a rapid quantitative immunoassay and SSCP analysis. Int J Cancer 69: 125-130
12. Diamandis EP and Levesque M (1995) Assessment of p53 protein overexpression by non-immunohistochemical methods. J Pathol 175: 93-94
13. Diamandis EP, Yu H and Sutherland DJA (1994) Detection of prostate specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat 32: 291-300
14. Diamandis EP, Yu H and Lopez-Otin C (1996) Prostate specific antigen - a new constituent of breast cyst fluid. Breast Cancer Res Treat 38: 259-264
15. Dressler LG, Seamer LC, Owens MA, Clark GM and McGuire WL (1988) DNA flow cytometry and prognostic factors in 1131 frozen breast cancer specimens. Cancer 61: 420-427
16. Ferguson RA, Yu H, Kalyvas M, Zammit S and Diamandis EP (1996) Ultrasensitive detection of prostate specific antigen by a new time resolved immunoflurometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin Chem 42: 675-684
17. Gasparini G, Pozza F and Harris AL (1993) Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85: 1206-1219
18. Greenblatt MS, Bennett WP, Hollstein M and Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878
19. Hartwell LH and Kastan MB (1994) Cell cycle control and cancer. Science 266: 1821-1828
20. Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
21. Karp JE and Broder S (1995) Molecular foundations of cancer: new targets for intervention. Nature Med 1: 309-320
22. Lane DP (1994) The regulation of p53 function. Int J Cancer 57: 623-627
23. Levesque MA, Clark GM, Yu H and Diamandis EP (1995a) Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators. Br J Cancer 72: 720-727
24. Levesque MA, D'Costa M, Angelopoulou K and Diamandis EP (1995b) Time-resolved immunofluorometric assay of p53. Clin Chem 41: 1720-1729
25. Levesque MA, Yu H, Clark GM and Diamandis EP (1998) ELISA-detected p53 protein accumulation: a prognostic factor in a large breast cancer cohort. J Clin Oncol 16: 2641-2650
26. Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Wu M and Welsh D (1994) The role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 69: 409-416
27. Lianidou ES, Levesque MA, Katsaros D, Angelopoulou K, Yu H, Genta F, Arisio R, Massobrio M, Bharaj B and Diamandis EP (1999) Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma. Anticancer Res 19: 749-756
28. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170
29. McGuire WL and Clark GM (1992) Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 326: 1756-1761
30. Oesterling JE (1989) Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923
31. Partin AW and Oesterling JE (1994) The clinical usefulness of prostate specific antigen: update 1994. J Urol 152: 1358-1368
32. Pollen JJ and Dreilinger A (1984) Immunohistochemical identification of prostatic acid phosphatase and prostate specific antigen in female periurethral gland. Urology 23: 303-304
33. Pummer K, Wirnsberger G, Purstner P, Stettner H and Wandschneider G (1992) False positive prostate specific antigen values in the sera of women with renal cell carcinoma. J Urol 148: 21-23
34. Sjögren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L and Bergh J (1996) The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88: 173-182
35. Soussi T, Legros Y, Lubin R, Ory K and Schlichtholz (1994) Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 57: 1-9
36. Thor AD, Moore DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH and Smith HS (1992) Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer. J Natl Cancer Inst 84: 845-855
37. Yu H and Diamandis EP (1995a) Prostate specific antigen immunoreactivity in amniotic fluid. Clin Chem 41: 204-210
38. Yu H and Diamandis EP (1995b) Prostate specific antigen in milk of lactating women. Clin Chem 41: 54-60
39. Yu H, Diamandis EP and Sutherland DJA (1994a) Immunoreactive prostate specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patients age. Clin Biochem 27: 75-79
40. Yu H, Diamandis EP, Zarghami N and Grass L (1994b) Induction of prostate specific antigen production by steroids and tumoxifen in the breast cancer cell lines. Breast Cancer Res Treat 32: 301-310
41. Yu H, Diamandis EP, Levesque MA, Asa SL, Monne M and Croee CM (1995a) Expression of the prostate-specific antigen gene by a primary ovarian carcinoma. Cancer Res 55: 1603-1606
42. Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJA, Levesque MA, Roagna R, Ponzone R and Sismondi P (1995b) Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 55: 2104-2110
43. Yu H, Diamandis EP, Levesque M, Giai M, Roagna R, Ponzone R, Sismondi P, Monne M and Croce M (1996) Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat 40: 171-178
44. Yu H, Levesque MA, Clark GM and Diamandis EP (1998) Prognostic value of prostate specific antigen for women with breast cancer - a large cohort study. Clin Cancer Res 4: 1489-1497
45. Zarghanti N, Grass L and Diamandis EP (1997) Steroid hormone regulation of prostate specific antigen gene expression in breast cancer. Br J Cancer 75: 579-588